Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1792 • ACR Convergence 2021
Participation in Psoriatic Arthritis (PART2) – a Cross-sectional Study of Work Impairment in Psoriatic Arthritis Patients in the Netherlands
Tamara van Hal¹, Michelle Mulder¹, Mark Wenink² and Johanna Vriezekolk¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Malden, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) can lead to pain, disability and a loss of quality of life [Rosen, Rheumatology 2012]. PsA can also lead to impairments…
Abstract Number: 1809 • ACR Convergence 2021
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Philip Mease¹, Ana-Maria Orbai², Oliver FitzGerald³, Mohamed Bedaiwi⁴, Dona L Fleishaker⁵, Rajiv Mundayat⁶, Pamela Young⁷ and Philip S Helliwell⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Division of Rheumatology, College of Medicine, King Saud University Medical City, Riyadh, Saudi Arabia, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of…
Abstract Number: 1827 • ACR Convergence 2021
Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort
Alexis Ogdie¹, William Tillett², Alun Passey³ and Patricia Gorecki⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Janssen Real World Evidence, HEMAR EMEA, High Wycombe, United Kingdom, ⁴Janssen Medical Affairs, London, United Kingdom
Background/Purpose: Skin and joint symptoms both contribute to the burden of disease in psoriatic arthritis (PsA).1 More severe skin symptoms in patients with both skin…
Abstract Number: 0183 • ACR Convergence 2021
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients
Merav Lidar¹, Jacob Aelion², Gareth Scott Tarr³, Kim Papp⁴, Lisa Barcomb⁵, Ahmed M. Soliman⁵, Wenjing Lu⁶, Ann Eldred⁵ and Andrew Ostor⁷, ¹Chaim Sheba Medical Center, Ramat Gan, Israel, ²Arthritis Clinic and West Tennessee Research Institute, Jackson, TN, ³Winelands Medical Research Centre and the Institute of Orthopaedics and Rheumatology (IOR), Winelands Medi-Clinic Orthopaedic Hospital, Stellenbosch, South Africa, ⁴K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ⁵Abbvie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, ⁷Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia
Background/Purpose: Risankizumab (RZB) is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. RZB is being investigated…
Abstract Number: 0571 • ACR Convergence 2021
The National Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2014-2016
Sofia Exarchou¹, Daniela Di Giuseppe², Gerd-Marie Alenius³, Eva Klingberg⁴, Valgerdur Sigurdardottir⁵, Sara Wedrén⁶, Ulf Lindström⁷, Carl Turesson⁸, Lennart Jacobsson⁷, Johan Askling² and Johan Karlsson Wallman⁹, ¹Lund University, Malmö, Sweden, ²Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Umeå University, Umeå, Sweden, Umeå, Sweden, ⁴University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, ⁵Uppsala University, Uppsala, Sweden and Falun Hospital, Falun, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁷University of Gothenburg, Gothenburg, Sweden, ⁸Lund University, Malm, Sweden, ⁹Lund University and Skane University Hospital, Hjarup, Sweden
Background/Purpose: Psoriatic arthritis (PsA) incidence estimates vary considerably, and nationwide estimates are sparse. In Sweden, PsA is typically diagnosed in specialized care, although a limited…
Abstract Number: 1005 • ACR Convergence 2021
CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration and Therapeutic Targeting
Viviana Marzaioli¹, Mary Canavan², Achilleas Floudas³, Keelin Flynn⁴, Ronan Mullan⁵, Douglas Veale⁶ and Ursula Fearon⁷, ¹Trinity College Dublin and University College Dublin, Dublin, Ireland, ²Trinity College, Santry, Ireland, ³Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁴The Centre for Arthritis and Rheumatic Disease, EULAR Centre of Excellence, St. Vincent’s University Hospital and University College Dublin, Ireland, Dublin, Ireland, ⁵Tallaght University Hospital, Dublin, Ireland, ⁶University College Dublin, Dublin, Ireland, ⁷Trinity College Dublin, Dublin, Ireland
Background/Purpose: Dendritic cells (DCs) are a heterogeneous population of professional antigen-presenting cells which are at the interface between innate and adaptive immunity. A specific subset…
Abstract Number: 1325 • ACR Convergence 2021
Osteoporosis in Psoriatic Arthritis
Sara M. Rojas Herrera¹, Ignacio Braña Abascal¹, Maria Priego Fernanddez-Martos¹, Delia Fernandez Lozano¹, Lara M. Chaves Chaparro¹, Raul Veroz Gonzalez¹, Juan J. Aznar Sanchez² and Eugenio Chamizo Carmona¹, ¹Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Merida, Spain
Background/Purpose: Osteoporosis (OP) is a frequently underestimated comorbidity in immune-mediated inflammatory diseases (IMIDs). Its association with IMIDs is worse characterized in Psoriatic Arthritis (PsA) than…
Abstract Number: 1342 • ACR Convergence 2021
Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Among Guselkumab-treated Patients: Pooled Analyses of VOYAGE 1 & 2 and DISCOVER 1 & 2 Through 1-Year
Philip Mease¹, Peter Foley², Kristian Reich³, Jerry Bagel⁴, Mark Lebwohl⁵, Ya-Wen Yang⁶, May Shawi⁷, Megan Miller⁸, Alexa Kollmeier⁹, Elizabeth Hsia⁸, Xie Xu⁸, Miwa Izutsu¹⁰, Paraneedharan Ramachandran¹⁰, Shihong Sheng⁸, Yin You⁸, Philip S Helliwell¹¹ and Wolf-Henning Boehncke¹², ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²University of Melbourne, Carlton, Australia, ³University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁴Psoriasis Treatment Center of Central New Jersey, Department of Dermatology, East Windsor, NJ, USA, East Windsor, NJ, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Janssen Global Services, LLC, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Janssen Research & Development, LLC, Immunology, Spring House, PA, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹²Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Guselkumab (GUS), an anti-interleukin (IL)-23p19-subunit mAb, demonstrated efficacy in VOYAGE (VOY) 1&2 patients (pts) with moderate to severe plaque psoriasis (PsO)1,2 and in DISCOVER…
Abstract Number: 1358 • ACR Convergence 2021
Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study
Maria Antonietta D'Agostino¹, Georg Schett², Corine Gaillez³, Philip Conaghan⁴, Esperanza Naredo⁵, Philippe Carron⁶, Ruben Burgos-Vargas⁷, Peter Mandl⁸, Javier Rosa⁹, Maarten Boers¹⁰, Punit Goyanka¹¹, Weibin Bao¹² and David Demanse³, ¹Rheumatology, Fondazione Policlinico Universitario “Gemelli”, IRCCS, Rome, Italy, ²Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ³Novartis Pharma AG, Basel, Switzerland, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Department of Rheumatology and Joint and Bone Research Unit, Hospital Fundación Jiménez Díaz and Autónoma University, Madrid, Spain, ⁶Department of Rheumatology, University Hospital Ghent, University of Ghent, Ghent, Belgium, ⁷Department of Rheumatology, General Hospital of Mexico, Ciudad de Mxico, Mexico, ⁸Medical University of Vienna, Vienna, Austria, ⁹Rheumatology Unit, Internal Medical Services, and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India, ¹²Novartis, East Hanover, NJ
Background/Purpose: Psoriatic arthritis (PsA) is characterized by inflammation of synovial membranes and entheseal sites leading to pain, structural damage, impairment of physical function and quality…
Abstract Number: 1775 • ACR Convergence 2021
Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis
Timothy Kwok¹, Mitchell Sutton², Richard Cook³, Daniel Pereira⁴ and Dafna Gladman⁵, ¹Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Isolated axial involvement exists in 2 to 5% of all psoriatic arthritis (PsA) patients. However, it is currently unknown whether patients with isolated axial…
Abstract Number: 1793 • ACR Convergence 2021
Impact of Gender and Age on Psoriatic Arthritis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Arthur Karasik¹, Isabelle Fortin², Proton Rahman³, Regan Arendse⁴, Emmanouil Rampakakis⁵, Odalis Asin-Milan⁶, Allen Lehman⁶, Francois Nantel⁷ and Meagan Rachich⁶, ¹Arthur Karasik Medicine Professional Corporation, Toronto, ON, Canada, ²CREQ, Rimouski, QC, Canada, ³Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…
Abstract Number: 1810 • ACR Convergence 2021
Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)
Monica Schwartzman¹, Zafir Abutalib² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²The Hospital For Special Surgery, New York, NY
Background/Purpose: The advent of targeted synthetics and biologics has greatly broadened the options for effective treatment in PsA. Guidelines published in 2018 by the American…
Abstract Number: 1828 • ACR Convergence 2021
Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Sergio Schwartzman¹, Atul Deodhar², Bernard Combe³, Ana Accioly⁴, Andris Kronbergs⁴, Boris Janos⁵, Danting Zhu⁴, David Sandoval Calderon⁴, Proton Rahman⁶ and Denis Poddubnyy⁷, ¹Self Employed 72nd Street Medical Associates, Scarsdale, NY, ²Oregon Health & Science University, Portland, OR, ³CHU Montpellier Montpellier University, Montpellier, France, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Calgary, AB, Canada, ⁶Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁷Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A approved for the treatment of psoriasis, psoriatic arthritis (PsA), active ankylosing spondylitis (AS)…
Abstract Number: 0201 • ACR Convergence 2021
Australian Psoriatic Arthritis (PsA) Biologic Disease-modifying Antirheumatic Drug (bDMARD) Treatment Pathways Using Sankey Diagrams and Predictive Analysis: A Combined Australian Rheumatology Association Database (ARAD) and Pharmaceutical Benefits Scheme (PBS) Analysis
Ashley Fletcher¹, Lyn March², Marissa Lassere³, Catherine Hill⁴, Claire Barrett⁵, Graeme Carroll⁶, Premarani Sinnathurai⁷ and Rachelle Buchbinder⁸, ¹Cabrini Health, Malvern, Australia, ²Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia, ³St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, ⁴Queen Elizabeth Hospital, Woodville, Australia, ⁵Redcliffe Hospital, University of Queensland, Margate Beach, Australia, ⁶Fiona Stanley Hospital, Perth, Australia, ⁷Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, ⁸Cabrini Health/Monash University, Malvern, Australia
Background/Purpose: To describe current bDMARD treatment patterns for ARAD participants with PsA, after combining with linked government PBS data.Methods: ARAD, a voluntary longitudinal observational database…
Abstract Number: 0575 • ACR Convergence 2021
World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
Olivier Fakih, Clement Prati, Daniel Wendling and Frank Verhoeven, Service de rhumatologie, CHU de Besançon, Besançon, France
Background/Purpose: There is little epidemiological data on mortality in spondyloarthritis (SpA). This study aimed to determine countries’ mortality rates of ankylosing spondylitis (AS) and psoriatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].